AR058379A1 - Derivados de arilpropionamida arilacrilamida arilpropinamida o arilmetilurea como inhibidores del factor xia. proceso de obtencion y composiciones farmaceuticas. - Google Patents
Derivados de arilpropionamida arilacrilamida arilpropinamida o arilmetilurea como inhibidores del factor xia. proceso de obtencion y composiciones farmaceuticas.Info
- Publication number
- AR058379A1 AR058379A1 ARP060105500A ARP060105500A AR058379A1 AR 058379 A1 AR058379 A1 AR 058379A1 AR P060105500 A ARP060105500 A AR P060105500A AR P060105500 A ARP060105500 A AR P060105500A AR 058379 A1 AR058379 A1 AR 058379A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- heterocycle
- alkyl
- independently
- nr8r9
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000008569 process Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 21
- 125000000623 heterocyclic group Chemical group 0.000 abstract 19
- 125000005842 heteroatom Chemical group 0.000 abstract 17
- 125000004432 carbon atom Chemical group C* 0.000 abstract 16
- 229910052717 sulfur Inorganic materials 0.000 abstract 16
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 13
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 12
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 11
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 8
- 125000004429 atom Chemical group 0.000 abstract 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000001960 7 membered carbocyclic group Chemical group 0.000 abstract 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 abstract 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 abstract 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- -1 carbocycle Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000009424 thromboembolic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/68—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75013005P | 2005-12-14 | 2005-12-14 | |
| US82116306P | 2006-08-02 | 2006-08-02 | |
| US86521106P | 2006-11-10 | 2006-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR058379A1 true AR058379A1 (es) | 2008-01-30 |
Family
ID=37944011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060105500A AR058379A1 (es) | 2005-12-14 | 2006-12-13 | Derivados de arilpropionamida arilacrilamida arilpropinamida o arilmetilurea como inhibidores del factor xia. proceso de obtencion y composiciones farmaceuticas. |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US7626039B2 (OSRAM) |
| EP (1) | EP1981854B1 (OSRAM) |
| JP (1) | JP5225098B2 (OSRAM) |
| KR (1) | KR20080087817A (OSRAM) |
| AR (1) | AR058379A1 (OSRAM) |
| AT (1) | ATE511502T1 (OSRAM) |
| AU (1) | AU2006325754B2 (OSRAM) |
| BR (1) | BRPI0620010A2 (OSRAM) |
| CA (1) | CA2633252A1 (OSRAM) |
| EA (1) | EA014245B1 (OSRAM) |
| IL (1) | IL192033A0 (OSRAM) |
| NO (1) | NO20082444L (OSRAM) |
| NZ (1) | NZ568595A (OSRAM) |
| PE (1) | PE20070811A1 (OSRAM) |
| TW (1) | TW200730477A (OSRAM) |
| WO (1) | WO2007070826A1 (OSRAM) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| JP5236293B2 (ja) * | 2005-01-13 | 2013-07-17 | ブリストル−マイヤーズ スクイブ カンパニー | Ｘｉａ因子阻害剤としての置換ビアリール化合物 |
| WO2007070816A2 (en) * | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Thiophene derivatives as factor xia inhibitors |
| JP2009519966A (ja) * | 2005-12-14 | 2009-05-21 | ブリストル−マイヤーズ スクイブ カンパニー | セリンプロテアーゼ阻害剤として有用な６員ヘテロ環 |
| CN101605779B (zh) * | 2006-12-15 | 2013-11-20 | 百时美施贵宝公司 | 作为凝血因子xia抑制剂的芳基丙酰胺、芳基丙烯酰胺、芳基丙炔酰胺或芳基甲基脲类似物 |
| MX2009012847A (es) * | 2007-06-13 | 2009-12-08 | Bristol Myers Squibb Co | Analogos dipeptidicos como inhibidores de factores de coagulacion. |
| CN102026996B (zh) * | 2008-03-13 | 2015-01-07 | 百时美施贵宝公司 | 作为凝血因子xia抑制剂的哒嗪衍生物 |
| MX2011011025A (es) * | 2009-04-20 | 2011-11-02 | Osi Pharmaceuticals Llc | Preparacion de c-piracin-metilaminas. |
| PL2481725T3 (pl) * | 2009-09-25 | 2015-08-31 | Astellas Pharma Inc | Podstawiony związek amidowy |
| CN102753555B (zh) | 2010-02-11 | 2018-01-12 | 百时美施贵宝公司 | 作为因子xia抑制剂的大环类 |
| LV14606B (lv) | 2011-05-17 | 2013-01-20 | Tetra, Sia | Jauns XII faktora inhibitors |
| EP2729448B1 (en) * | 2011-07-06 | 2015-09-09 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
| TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑 |
| TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之新穎巨環化合物 |
| EP3309148A1 (en) | 2011-10-14 | 2018-04-18 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| EP2766347B1 (en) | 2011-10-14 | 2016-05-04 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| EP2899183B1 (en) | 2011-10-14 | 2018-09-19 | Bristol-Myers Squibb Company | Substituted Tetrahydroisoquinoline Compounds as Factor Xia Inhibitors |
| EP2794597B1 (en) * | 2011-12-21 | 2017-11-15 | ONO Pharmaceutical Co., Ltd. | Pyridinone and pyrimidinone derivatives as factor xia inhibitors |
| GB2497806A (en) * | 2011-12-21 | 2013-06-26 | Ono Pharmaceutical Co | Pyridinone and pyrimidinone derivatives as factor XIa inhibitors |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| GB201209138D0 (en) | 2012-05-24 | 2012-07-04 | Ono Pharmaceutical Co | Compounds |
| GB201212081D0 (en) * | 2012-07-06 | 2012-08-22 | Kalvista Pharmaceuticals Ltd | New polymorph |
| EA028581B1 (ru) | 2012-08-03 | 2017-12-29 | Бристол-Маерс Сквибб Компани | ДИГИДРОПИРИДОН Р1 В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА XIa |
| UY34959A (es) | 2012-08-03 | 2014-01-31 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Dihidropiridona p1 como inhibidores del factor xia |
| WO2014059202A1 (en) | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| DK2906551T3 (en) | 2012-10-12 | 2018-05-22 | Bristol Myers Squibb Co | CRYSTALLIC FORMS OF A FACTOR XIA INHIBITOR |
| EP2906541B1 (en) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| GB201300304D0 (en) * | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
| CA2905242C (en) | 2013-03-15 | 2016-11-29 | Pfizer Inc. | Indole compounds that activate ampk |
| US9738655B2 (en) | 2013-03-25 | 2017-08-22 | Bristol-Myers Squibb Company | Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors |
| EA201300843A1 (ru) * | 2013-08-01 | 2015-04-30 | Арсений Валерьевич Айбушев | Карбамоилфенильные производные для остановки, предотвращения и профилактики кровотечений или усиления системы гемостаза |
| GB2517908A (en) * | 2013-08-14 | 2015-03-11 | Kalvista Pharmaceuticals Ltd | Bicyclic inhibitors |
| WO2015054087A1 (en) | 2013-10-07 | 2015-04-16 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
| UY40230A (es) | 2014-01-31 | 2023-08-15 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Macrociclos con grupos P2’ heterocíclicos como inhibidores del factor XIa y composiciones farmacéuticas que los comprenden |
| NO2760821T3 (OSRAM) | 2014-01-31 | 2018-03-10 | ||
| WO2015123091A1 (en) | 2014-02-11 | 2015-08-20 | Merck Sharp & Dohme Corp. | Factor xia inhibitors |
| EP3104703B1 (en) | 2014-02-11 | 2020-11-18 | Merck Sharp & Dohme Corp. | Factor xia inhibitors |
| EP3110804A4 (en) * | 2014-02-25 | 2017-11-22 | Achillion Pharmaceuticals, Inc. | Carbamate, ester, and ketone compounds for treatment of complement mediated disorders |
| WO2015160636A1 (en) | 2014-04-16 | 2015-10-22 | Merck Sharp & Dohme Corp. | Factor ixa inhibitors |
| US10093683B2 (en) | 2014-04-22 | 2018-10-09 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
| DK3169666T3 (en) | 2014-07-15 | 2018-07-30 | Gruenenthal Gmbh | SUBSTITUTED AZASPIRO (4.5) DECAN DERIVATES |
| TW201607923A (zh) | 2014-07-15 | 2016-03-01 | 歌林達有限公司 | 被取代之氮螺環（４．５）癸烷衍生物 |
| WO2016015593A1 (en) | 2014-07-28 | 2016-02-04 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
| TW201613977A (en) | 2014-08-07 | 2016-04-16 | Novartis Ag | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use |
| TN2017000019A1 (en) | 2014-08-07 | 2018-07-04 | Novartis Ag | Angiopoietin-like 4 antibodies and methods of use. |
| ES2714283T3 (es) | 2014-09-04 | 2019-05-28 | Bristol Myers Squibb Co | Macrociclos de diamida que son inhibidores de FXIa |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| EP3231803B1 (en) | 2014-12-10 | 2020-07-01 | ONO Pharmaceutical Co., Ltd. | Dihydroindolizinone derivative |
| US10189819B2 (en) | 2014-12-10 | 2019-01-29 | Merck Sharp & Dohme, Corp. | Factor IXa inhibitors |
| US11135206B2 (en) * | 2015-05-26 | 2021-10-05 | Kaohsiung Medical University | Pyrazolo[4,3-c]quinoline derivatives for inhibition of β-glucuronidase |
| EP3310777B1 (en) | 2015-06-19 | 2019-10-09 | Bristol-Myers Squibb Company | Diamide macrocycles as factor xia inhibitors |
| JOP20200312A1 (ar) | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
| CN107849026B (zh) | 2015-07-29 | 2021-01-01 | 百时美施贵宝公司 | 携带烷基或环烷基p2′部分的因子xia大环抑制剂 |
| US10676477B2 (en) | 2015-07-29 | 2020-06-09 | Bristol-Myers Squibb Company | Factor XIa macrocycle inhibitors bearing a non-aromatic P2' group |
| US10344039B2 (en) | 2015-10-29 | 2019-07-09 | Merck Sharp & Dohme Corp. | Macrocyclic spirocarbamate derivatives as factor XIa inhibitors, pharmaceutically acceptable compositions and their use |
| US10214512B2 (en) | 2015-10-29 | 2019-02-26 | Merck Sharp & Dohme Corp. | Factor XIA inhibitors |
| WO2017095760A1 (en) * | 2015-12-02 | 2017-06-08 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
| WO2017123518A1 (en) * | 2016-01-11 | 2017-07-20 | The Rockefeller University | Aminotriazole immunomodulators for treating autoimmune diseases |
| TW201802121A (zh) | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
| BR112018071678B1 (pt) | 2016-08-19 | 2021-01-26 | Gilead Sciences, Inc. | compostos terapêuticos úteis para o tratamento profilático ou terapêutico de uma infecção por vírus hiv e suas composições farmacêuticas |
| EP3500556B1 (en) | 2016-08-22 | 2023-08-02 | Merck Sharp & Dohme LLC | Pyridine-1-oxide derivatives and their use as factor xia inhibitors |
| JP7139332B2 (ja) | 2016-12-23 | 2022-09-20 | ノバルティス アーゲー | 第ｘｉ因子抗体および使用方法 |
| AR112413A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas sólidas de un inhibidor de la cápside del vih |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| KR102587510B1 (ko) | 2018-02-15 | 2023-10-11 | 길리애드 사이언시즈, 인코포레이티드 | 피리딘 유도체 및 hiv 감염을 치료하기 위한 그의 용도 |
| CA3281991A1 (en) | 2018-02-16 | 2025-11-29 | Gilead Sciences, Inc. | Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviridae viral infection |
| JP2021530523A (ja) | 2018-07-16 | 2021-11-11 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖの処置のためのカプシド阻害剤 |
| EP4643882A2 (en) | 2019-11-26 | 2025-11-05 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of hiv |
| CA3181690A1 (en) | 2020-06-25 | 2021-12-30 | Chienhung CHOU | Capsid inhibitors for the treatment of hiv |
| US20240025917A1 (en) * | 2020-11-19 | 2024-01-25 | Merck Sharp & Dohme Llc | Plasma kallikrein inhibitors |
| FI4445900T3 (fi) | 2021-12-03 | 2025-08-05 | Gilead Sciences Inc | Terapeuttisia yhdisteitä hiv-virusinfektiota varten |
| WO2023102523A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| CN118355020A (zh) | 2021-12-03 | 2024-07-16 | 吉利德科学公司 | Hiv病毒感染的治疗性化合物 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001505585A (ja) | 1996-12-16 | 2001-04-24 | 藤沢薬品工業株式会社 | 新規アミド化合物およびそれらの一酸化窒素シンターゼ阻害剤としての用途 |
| US6593291B1 (en) | 1997-02-06 | 2003-07-15 | Entremed, Inc. | Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease |
| ZA985247B (en) * | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
| RU2263111C2 (ru) | 1998-06-12 | 2005-10-27 | Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик Сас | Имидазольные производные |
| RU2242481C2 (ru) * | 1998-06-16 | 2004-12-20 | Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик Сас | Аналоги циклического соматостатина |
| AUPQ142599A0 (en) * | 1999-07-05 | 1999-07-29 | Fujisawa Pharmaceutical Co., Ltd. | New amide compounds |
| US20040132788A1 (en) | 1999-10-11 | 2004-07-08 | Chabrier De Lassauniere Pierre-Etienne | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
| CA2417204A1 (en) * | 2000-08-01 | 2002-02-07 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R | Imidazolyl derivatives |
| NZ534238A (en) * | 2002-01-31 | 2006-09-29 | Morphochem Ag Komb Chemie | Compounds that inhibit factor Xa activity |
| WO2004071448A2 (en) * | 2003-02-12 | 2004-08-26 | Transtech Pharma Inc. | Substituted azole derivatives as inhibitors of protein tyrosine phosphatases |
| US20040180855A1 (en) * | 2003-02-19 | 2004-09-16 | Schumacher William A. | Methods of treating thrombosis with reduced risk of increased bleeding times |
| US7138412B2 (en) * | 2003-03-11 | 2006-11-21 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives useful as serine protease inhibitors |
| US7129264B2 (en) * | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
| US7371743B2 (en) * | 2004-02-28 | 2008-05-13 | Boehringer Ingelheim International Gmbh | Carboxylic acid amides, the preparation thereof and their use as medicaments |
| LT2653465T (lt) * | 2004-03-15 | 2016-09-12 | Janssen Pharmaceutica Nv | Opioidinio receptoriaus moduliatoriai |
| US7417063B2 (en) * | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
| KR100966749B1 (ko) * | 2004-05-26 | 2010-06-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신나미드 화합물 |
| US7453002B2 (en) * | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| US7429604B2 (en) * | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| JP5197014B2 (ja) | 2004-12-10 | 2013-05-15 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | ヒストンデアセチラーゼ（ｈｄａｃ）阻害剤としての複素環誘導体 |
| JP5236293B2 (ja) | 2005-01-13 | 2013-07-17 | ブリストル−マイヤーズ スクイブ カンパニー | Ｘｉａ因子阻害剤としての置換ビアリール化合物 |
| JP2009519966A (ja) | 2005-12-14 | 2009-05-21 | ブリストル−マイヤーズ スクイブ カンパニー | セリンプロテアーゼ阻害剤として有用な６員ヘテロ環 |
| WO2007070816A2 (en) | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Thiophene derivatives as factor xia inhibitors |
-
2006
- 2006-12-13 AR ARP060105500A patent/AR058379A1/es unknown
- 2006-12-13 EP EP06846594A patent/EP1981854B1/en active Active
- 2006-12-13 KR KR1020087016921A patent/KR20080087817A/ko not_active Withdrawn
- 2006-12-13 CA CA002633252A patent/CA2633252A1/en not_active Abandoned
- 2006-12-13 AU AU2006325754A patent/AU2006325754B2/en not_active Ceased
- 2006-12-13 BR BRPI0620010-9A patent/BRPI0620010A2/pt not_active IP Right Cessation
- 2006-12-13 JP JP2008545955A patent/JP5225098B2/ja not_active Expired - Fee Related
- 2006-12-13 NZ NZ568595A patent/NZ568595A/en unknown
- 2006-12-13 AT AT06846594T patent/ATE511502T1/de not_active IP Right Cessation
- 2006-12-13 WO PCT/US2006/062005 patent/WO2007070826A1/en not_active Ceased
- 2006-12-13 EA EA200801530A patent/EA014245B1/ru not_active IP Right Cessation
- 2006-12-13 US US11/610,027 patent/US7626039B2/en active Active
- 2006-12-14 PE PE2006001610A patent/PE20070811A1/es not_active Application Discontinuation
- 2006-12-14 TW TW095146901A patent/TW200730477A/zh unknown
-
2008
- 2008-05-28 NO NO20082444A patent/NO20082444L/no not_active Application Discontinuation
- 2008-06-10 IL IL192033A patent/IL192033A0/en unknown
-
2009
- 2009-10-05 US US12/573,230 patent/US7842708B2/en active Active
-
2010
- 2010-10-08 US US12/900,542 patent/US8252830B2/en active Active
-
2012
- 2012-07-03 US US13/540,871 patent/US8604056B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EA200801530A1 (ru) | 2008-12-30 |
| US20100022506A1 (en) | 2010-01-28 |
| TW200730477A (en) | 2007-08-16 |
| WO2007070826B1 (en) | 2007-08-16 |
| US7626039B2 (en) | 2009-12-01 |
| BRPI0620010A2 (pt) | 2011-11-22 |
| EA014245B1 (ru) | 2010-10-29 |
| PE20070811A1 (es) | 2007-08-13 |
| US8252830B2 (en) | 2012-08-28 |
| US20110028446A1 (en) | 2011-02-03 |
| EP1981854A1 (en) | 2008-10-22 |
| AU2006325754A1 (en) | 2007-06-21 |
| KR20080087817A (ko) | 2008-10-01 |
| NZ568595A (en) | 2010-04-30 |
| AU2006325754B2 (en) | 2012-04-12 |
| NO20082444L (no) | 2008-09-12 |
| WO2007070826A1 (en) | 2007-06-21 |
| CA2633252A1 (en) | 2007-06-21 |
| JP5225098B2 (ja) | 2013-07-03 |
| IL192033A0 (en) | 2008-12-29 |
| US7842708B2 (en) | 2010-11-30 |
| EP1981854B1 (en) | 2011-06-01 |
| ATE511502T1 (de) | 2011-06-15 |
| US20080161373A1 (en) | 2008-07-03 |
| US20120270853A1 (en) | 2012-10-25 |
| JP2009519967A (ja) | 2009-05-21 |
| US8604056B2 (en) | 2013-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR058379A1 (es) | Derivados de arilpropionamida arilacrilamida arilpropinamida o arilmetilurea como inhibidores del factor xia. proceso de obtencion y composiciones farmaceuticas. | |
| ES2525763T3 (es) | Derivados del ácido fenilalcanoico sustituido y sus usos para el tratamiento de enfermedades respiratorias | |
| AR067329A1 (es) | Analogos dipeptidos como inhibidores del factor de coagulacion | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR053014A1 (es) | Compuestos de pirazol inhibidores de raf quinasa | |
| AR064304A1 (es) | Formulaciones de ansamicina y sus metodos de uso | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| DOP2007000079A (es) | Compuestos fenil amido heterocíclicos condensados | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| AR067093A1 (es) | N-(2-(hetaril) arilsulfonamidas y n-(2-( heteraril) hetaril) arilsulfonamidas | |
| AR102467A1 (es) | Métodos para tratar infecciones por el virus filoviridae | |
| ES2823850T3 (es) | Moduladores de regulador de conductancia transmembrana de fibrosis quística | |
| AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. | |
| AR059328A1 (es) | Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp | |
| AR062928A1 (es) | Inhibidores de la actividad quinasa utiles en el tratamiento de trastornos mediados por mecanismos de ikk2 | |
| AR053710A1 (es) | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos | |
| AR070274A1 (es) | Derivados arilamida diazepinopirimidona sustituidos utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, provocadas por la actividad anormal de quinasas gsk3beta, medicamentos que los contienen y proceso de preparacion e intermediarios. | |
| AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
| AR063531A1 (es) | Derivados de anilinopiperazina y composicion farmaceutica | |
| AR042956A1 (es) | Inhibidores de girasa y usos de los mismos | |
| AR070273A1 (es) | Derivados de heteroarilamida diazepinopirimidinona sustituidos utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, provocadas por la actividad anormal de quinasas gsk3beta, medicamentos que los contienen y proceso de preparacion e intermediarios. | |
| AR083525A1 (es) | Derivados de acido picolinico sustituidos con heterociclos, metodo para prepararlos, uso de los mismos como herbicidas y composiciones herbicidas que los contienen | |
| AR087309A1 (es) | Compuesto heterociclico de anillos condensados sustituido, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento para el tratamiento de enfermedades neurogenerativas y aterosclerosis | |
| AR075583A1 (es) | Derivados de isoxazol/o-piridina con eslabon etilo o etenilo | |
| AR067646A1 (es) | Ariloxazoles sustituidos y su uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |